276 related articles for article (PubMed ID: 17516714)
1. Certolizumab pegol: in Crohn's disease.
Blick SK; Curran MP
BioDrugs; 2007; 21(3):195-201; discussion 202-3. PubMed ID: 17516714
[TBL] [Abstract][Full Text] [Related]
2. Certolizumab pegol for the management of Crohn's disease in adults.
Rivkin A
Clin Ther; 2009 Jun; 31(6):1158-76. PubMed ID: 19695385
[TBL] [Abstract][Full Text] [Related]
3. Maintenance therapy with certolizumab pegol for Crohn's disease.
Schreiber S; Khaliq-Kareemi M; Lawrance IC; Thomsen OØ; Hanauer SB; McColm J; Bloomfield R; Sandborn WJ;
N Engl J Med; 2007 Jul; 357(3):239-50. PubMed ID: 17634459
[TBL] [Abstract][Full Text] [Related]
4. Certolizumab pegol in Crohn's disease.
Patel VK; Ghosh S
Drugs Today (Barc); 2008 Nov; 44(11):837-44. PubMed ID: 19180261
[TBL] [Abstract][Full Text] [Related]
5. Certolizumab pegol: new drug. As a last resort in Crohn's disease: continue to use other TNF alpha inhibitors.
Prescrire Int; 2009 Jun; 18(101):108-10. PubMed ID: 19637418
[TBL] [Abstract][Full Text] [Related]
6. Certolizumab pegol: a TNF-{alpha} antagonist for the treatment of moderate-to-severe Crohn's disease.
Smith LS; Nelson M; Dolder CR
Ann Pharmacother; 2010 Feb; 44(2):333-42. PubMed ID: 20118143
[TBL] [Abstract][Full Text] [Related]
7. Certolizumab pegol for the treatment of Crohn's disease.
Sandborn WJ; Feagan BG; Stoinov S; Honiball PJ; Rutgeerts P; Mason D; Bloomfield R; Schreiber S;
N Engl J Med; 2007 Jul; 357(3):228-38. PubMed ID: 17634458
[TBL] [Abstract][Full Text] [Related]
8. Certolizumab pegol: in rheumatoid arthritis.
Duggan ST; Keam SJ
BioDrugs; 2009; 23(6):407-17. PubMed ID: 19894782
[TBL] [Abstract][Full Text] [Related]
9. Pegylation of biological molecules and potential benefits: pharmacological properties of certolizumab pegol.
Pasut G
BioDrugs; 2014 Apr; 28 Suppl 1():S15-23. PubMed ID: 24687235
[TBL] [Abstract][Full Text] [Related]
10. Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease.
Behm BW; Bickston SJ
Cochrane Database Syst Rev; 2008 Jan; (1):CD006893. PubMed ID: 18254120
[TBL] [Abstract][Full Text] [Related]
11. [Certolizumab pegol--new possibilities in the treatment of Crohn's disease].
Lazebnik LB; Kniazev OV
Eksp Klin Gastroenterol; 2012; (3):100-5. PubMed ID: 22830233
[No Abstract] [Full Text] [Related]
12. Certolizumab pegol, a monthly subcutaneously administered Fc-free anti-TNFalpha, improves health-related quality of life in patients with moderate to severe Crohn's disease.
Rutgeerts P; Schreiber S; Feagan B; Keininger DL; O'Neil L; Fedorak RN;
Int J Colorectal Dis; 2008 Mar; 23(3):289-96. PubMed ID: 18071721
[TBL] [Abstract][Full Text] [Related]
13. Continuous therapy with certolizumab pegol maintains remission of patients with Crohn's disease for up to 18 months.
Lichtenstein GR; Thomsen OØ; Schreiber S; Lawrance IC; Hanauer SB; Bloomfield R; Sandborn WJ;
Clin Gastroenterol Hepatol; 2010 Jul; 8(7):600-9. PubMed ID: 20117244
[TBL] [Abstract][Full Text] [Related]
14. A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease.
Schreiber S; Rutgeerts P; Fedorak RN; Khaliq-Kareemi M; Kamm MA; Boivin M; Bernstein CN; Staun M; Thomsen OØ; Innes A;
Gastroenterology; 2005 Sep; 129(3):807-18. PubMed ID: 16143120
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of pharmacokinetics and pharmacodynamics and clinical efficacy of certolizumab pegol for Crohn's disease.
Tun GS; Lobo AJ
Expert Opin Drug Metab Toxicol; 2015 Feb; 11(2):317-27. PubMed ID: 25586216
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of certolizumab pegol in rheumatoid arthritis: meeting rheumatologists' requirements in routine clinical practice.
Punzi L; Lapadula G; Mathieu A
BioDrugs; 2014 Apr; 28 Suppl 1():S25-37. PubMed ID: 24687236
[TBL] [Abstract][Full Text] [Related]
17. Certolizumab pegol: a polyethylene glycolated Fab' fragment of humanized anti-tumor necrosis factor alpha monoclonal antibody for the treatment of Crohn's disease.
Baker DE
Rev Gastroenterol Disord; 2008; 8(4):240-53. PubMed ID: 19107098
[TBL] [Abstract][Full Text] [Related]
18. Certolizumab pegol.
Goel N; Stephens S
MAbs; 2010; 2(2):137-47. PubMed ID: 20190560
[TBL] [Abstract][Full Text] [Related]
19. Increased response and remission rates in short-duration Crohn's disease with subcutaneous certolizumab pegol: an analysis of PRECiSE 2 randomized maintenance trial data.
Schreiber S; Colombel JF; Bloomfield R; Nikolaus S; Schölmerich J; Panés J; Sandborn WJ;
Am J Gastroenterol; 2010 Jul; 105(7):1574-82. PubMed ID: 20234346
[TBL] [Abstract][Full Text] [Related]
20. Certolizumab Pegol: A Review in Moderate to Severe Plaque Psoriasis.
Lee A; Scott LJ
BioDrugs; 2020 Apr; 34(2):235-244. PubMed ID: 32207094
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
